Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 1
2009 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost.
Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Feldman SR, et al. Expert Opin Pharmacother. 2003 Sep;4(9):1525-33. doi: 10.1517/14656566.4.9.1525. Expert Opin Pharmacother. 2003. PMID: 12943482 Review.
New biological agents add to the treatment options for psoriasis; however, they raise the already considerable cost of managing the disease. ...Methotrexate, psoralen plus UVA, alefacept, etanercept and infliximab are appropriate second-l …
New biological agents add to the treatment options for psoriasis; however, they raise the already considerable cost
Anti-TNF agents for the treatment of psoriasis.
Kircik LH, Del Rosso JQ. Kircik LH, et al. J Drugs Dermatol. 2009 Jun;8(6):546-59. J Drugs Dermatol. 2009. PMID: 19537380 Review.
The annual cost of treating psoriasis may exceed $3 billion annually. Immunologic mechanisms are now accepted as the pathophysiologic basis for the development of psoriatic disease. ...Combination therapy should also be considered when managing
The annual cost of treating psoriasis may exceed $3 billion annually. Immunologic mechanisms are now accepted as the pathophys …
Initiative for quality in psoriasis and psoriatic arthritis.
Boehncke WH, Adebajo A, Cauli A, Nash P, Salvarani C, Kavanaugh AF. Boehncke WH, et al. J Rheumatol. 2008 Jul;35(7):1431-3. J Rheumatol. 2008. PMID: 18609739
Psoriasis is a common and severe skin disease. Up to 30% of psoriasis patients develop psoriatic arthritis (PsA), another severe disease that contributes significantly to the burden of psoriatic disease in patients. ...These are th
Psoriasis is a common and severe skin disease. Up to 30% of psoriasis patients develop psoriatic arthritis (PsA)